2015

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P. Arthritis Rheumatol. 2015 Nov;67(11):2855-60.

Genetic Factors for the Severity of ACPA-negative Rheumatoid Arthritis in 2 Cohorts of Early Disease: A Genome-wide Study.

de Rooy DP, Tsonaka R, Andersson ML, Forslind K, Zhernakova A, Frank-Bertoncelj M, de Kovel CG, Koeleman BP, van der Heijde DM, Huizinga TW, Toes RE, Houwing-Duistermaat JJ, Ospelt C, Svensson B, van der Helm-van Mil AH. J Rheumatol. 2015 Aug;42(8):1383-91.

Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial.

Levitsky A, Forslind K, van Vollenhoven RF; SWEFOT trial group. Scand J Rheumatol. 2015;44(5):348-53.

The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis.

van Steenbergen HW, Ajeganova S, Forslind K, Svensson B, van der Helm-van Mil AH. Ann Rheum Dis. 2015 Jan;74(1):e3.

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF. Ann Rheum Dis. 2015 Jun;74(6):1102-9.

Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.

Saevarsdottir S, Rezaei H, Geborek P, Petersson I, Ernestam S, Albertsson K, Forslind K, van Vollenhoven RF; SWEFOT study group. Ann Rheum Dis. 2015 Aug;74(8):1509-14.